NR3C2 and congestive heart failure: At enrolment, 3 of 4 CHF [beta-blocker, renin–angiotensin–aldosterone and/or neprilysin inhibitor (RAAS/ARNI) or mineralocorticoid receptor antagonist (MRA)] pillars were already started in participants.